Section Arrow
SGP.NASDAQ
- SpyGlass Pharma Inc
Quotes are at least 15-min delayed:2026/03/28 10:29 EDT
Regular Hours
Last
 22.61
-2.59 (-10.28%)
Day High 
24.63 
Prev. Close
25.2 
1-M High
29.105 
Volume 
95.37K 
Bid
9.2
Ask
35.82
Day Low
21.29 
Open
24.63 
1-M Low
22.41 
Market Cap 
839.60M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 25.99 
20-SMA 26.43 
50-SMA -- 
52-W High 32.44 
52-W Low 20.16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.92/-2.39
Enterprise Value
843.05M
Balance Sheet
Book Value Per Share
-2.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ITRMIterum Therapeutics plc0.0356-0.1404-79.77%-- 
ARTLArtelo Biosciences Inc10.54+7.35+230.41%-- 
ONCOOnconetix Inc1.94-1.28-39.75%0PE
RCKTRocket Pharmaceuticals3.77-0.92-19.62%-- 
ADMAADMA Biologics9.25+0.96+11.58%13.87PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company isdeveloping two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.